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Recently, the administration of high-dose cyclophosphamide (Cy) after T cellereplete haploidentical stem cell
infusion has been reported to be feasible and effective. In the original study, bone marrow (BM) was used as
the source of stem cells. Here, we retrospectively analyzed the use of BM versus peripheral blood stem cells
(PBSCs) in a cohort of patients receiving haploidentical T cellereplete transplantation after a non-
myeloablative conditioning regimen with postinfusion Cy. In the PBSC versus BM groups, the incidence of
acute graft-versus-host disease (GVHD) was 33% versus 25%, respectively, and the incidence of chronic GVHD
was 13% versus 13%, respectively. The median time to achieve a safe and unsupported absolute neutrophil and
platelet count was 20 versus 21 days and 27 versus 29 days, respectively. The incidence of engraftment was
also similar in the 2 cohorts. The 1-year nonrelapse mortality rate was 12% versus 22%, respectively (P ¼ .96).
Finally, nonsigniﬁcant differences in survival were observed. In conclusion, the use of PBSCs instead of BM
after T cellereplete haploidentical transplantation did not appear to be detrimental in terms of either GVHD
or engraftment rate. PBSCs could be a valid alternative to BM after transplantation from a haploidentical
donor using postinfusion Cy.
 2014 American Society for Blood and Marrow Transplantation.INTRODUCTION manipulation [7-9]. Bone marrow (BM), associated or not
Transplantation from alternative donors has been
attempted for years in patients with hematological malig-
nancies who lack HLA-identical donors. Whereas trials
conducted without speciﬁc approaches have produced
disappointing results [1], feasibility and some degree of efﬁ-
cacy have been achieved through extensive T cell depletion
using various ex vivo selection strategies [2-5] or using antieT
cell antibodies [6,7]. In these different methods, peripheral
blood stem cells (PBSCs) were the preferred stem cell source
because they enable the collection of a large number of CD34-
positive cells for ex vivo manipulation, allowing deep T cell
depletion while preserving a rich graft. However, logistical
concerns, a lack of reproducibility, and problems associated
with immune reconstitution have hampered the wide
dissemination of this treatment modality.
More recently, different strategies have been developed
to perform haploidentical transplantation without graftedgments on page 728.
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14.02.001with PBSCs and primed or unprimed, has been used as the
stem cell source in most of these methods [8,9]. When PBSCs
were used alone, graft-versus-host disease (GVHD) prophy-
laxis was usually strengthened by the ex vivo partial T cell
depletion of the graft or by the administration of more potent
postgraft immune suppression [4,7].
For years, researchers at Johns Hopkins University have
investigated the use of postgraft cyclophosphamide (Cy) [10]
in the context of allogeneic transplantation. Recently, in-
vestigators from Johns Hopkins University pioneered the use
of high-dose Cy after T cellereplete haploidentical stem cell
infusion [11]. One of the key characteristics of this program
was the use of BM as the stem cell source to reduce the risk of
acute (aGVHD) and/or chronic graft-versus-host disease
(cGVHD). Engraftment occurred rather rapidly, with median
times to a safe absolute neutrophil count (ANC) and to an
acceptable untransfused platelet count of 15 and 24 days,
respectively. In this program, the cumulative incidences of
neutrophil and platelet engraftment exceeded 90% and 80%,
respectively. Among a large number of patients who under-
went transplantation, the incidences of severe aGVHD and
cGVHD were remarkably low (34% and 5%, respectively) [11].
In a more recent group of T cellereplete haploidentical
transplant recipients who received postinfusion Cy, a smallTransplantation.
Table 1
Patient Characteristics
Characteristic BM PBSC P
Value
No. of patients 46 23
Age, median (range), yr 44 (19-68) 54 (25-65) .06
Disease .10
HL 23 (50%) 6 (27%)
NHL 15 (33%) 9 (35%)
CLL 1 (2%) 3 (12%)
AML/MDS 2 (4%) 2 (19%)
MM 2 (4%) 2 (8%)
ALL 2 (4%) 0
Previous HDC 34 of 46 (74%) 8 of 23 (35%) .002
Previous ALLO 1 of 46 (2%) 4 of 23 (17%) .022
Tandem auto-allo 15 of 46 (33%) 2 of 23 (9%) .03
Disease status at haplo .6
CR 28 (61%) 13 (57%)
PR 11 (24%) 7 (30%)
SD/PD 7 (15%) 3 (13%)
HCT-CI, median (range) 1 (0-5) 3 (0-6) .008
HLA mismatches,
median (range)
4 (3-6) 4 (4-6) .10
Conditioning regimen
FCyTBI 46 23 NA
Sex D/R .90
F/F 11 (24%) 4 (17%)
F/M 16 (35%) 5 (22%)
M/F 12 (26%) 6 (26%)
M/M 21 (46%) 8 (35%)
CMV D/R
þ/þ 27 (59%) 11 (48%) .60
þ/ 6 (13%) 3 (13%)
/þ 8 (17%) 4 (17%)
/ 5 (11%) 5 (22%)
ABO compatibility*
Compatible 31 (67%) 14 (61%) .80
Minor 9 (20%) 6 (26%)








34 (17-92) 273 (119-530) <.0001
Post-transplantation IS
CsA 12 (26%) 23 (100%) <.0001
FK 34 (74%) 0
Follow-up, median
(range), d
721 (365-728) 332 (135-498) <.0001
BM indicates bone marrow; PBSC, peripheral blood stem cells; HL, Hodgkin
lymphoma; NHL, non-Hodgkin lymphoma; MM, multiple myeloma; CLL,
chronic lymphocytic leukemia; AML, acute myeloid leukemia; MDS, mye-
lodysplastic syndrome; ALL, acute lymphoblastic leukemia; HDC, high-dose
chemotherapy; FCyTBI, ﬂudarabine, cyclophosphamide, and low-dose total
body irradiation; D/R, donor/recipient; IS, immunesuppression; CsA,
cyclosporine A; FK, tacrolimus; HCT-CI, hematopoietic cell transplantation-
comorbidity index.
Data presented are n (%) unless otherwise indicated.
* One patient in the BM group with bidirectional ABO incompatibility was
included in the major incompatibility group.
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conditioning regimen and received a PBSC graft [12]. The
median times to neutrophil and platelet engraftment were
16 days and 27 days, respectively. The incidences of aGVHD
(30%) and cGVHD (35%) were acceptable.
In the present study, we retrospectively analyzed the
use of 2 different stem cell sources in a cohort of patients
from 2 institutions; the patients underwent haploidentical
T cellereplete transplantation after a nonmyeloablative
conditioning (NMAC) regimen with postinfusion Cy. The
aim of this study was to compare the incidences of GVHD
and engraftment between patients who underwent trans-
plantation with PBSCs or with BM.
PATIENTS AND METHODS
From April 2009 until April 2013, 69 consecutive patients undergoing
T cellereplete haploidentical transplantation at 2 institutions for hemato-
logical malignancies with poor prognoses were analyzed. Every patient
provided informed consent.
Inclusion Criteria
Patients were candidates for haploidentical allogeneic HSCT if they met
the following criteria: (1) they lacked an HLA-matched related or unrelated
donor (in cases of previous allogeneic HSCT, the initial donor was dis-
carded); (2) they had a history of disease relapse after several chemother-
apeutic lines or after a previous autologous or allogeneic HSCT; and (3) they
were refractory to conventional salvage chemotherapy and were, thus,
candidates for an auto-allo strategy consisting of high-dose melphalan
(200 mg/m2) followed by haploidentical transplantation.
Patients were ineligible if they had active uncontrolled infections, a
central nervous system disease, a Karnofsky performance status <60, or
severe organ dysfunction, including a left ventricular ejection fraction<40%,
carbon monoxide diffusion capacity <50%, or creatinine clearance <50 mL/
min. The comorbidity index of each patient was calculated using the he-
matopoietic cell transplantation-comorbidity index system [13].
Conditioning Regimen and GVHD Prophylaxis
The conditioning regimen consisted of Cy 14.5 mg/kg on days -5 and -6,
ﬂudarabine 30 mg/m2 from day 6 to day 2, and low-dose total body
irradiationTBI (2 Gy) on day -1. The GVHD prophylaxis consisted of Cy
50 mg/kg administered on days þ3 and þ4, tacrolimus (Humanitas Cancer
Center), or cyclosporine A (CsA; Institut Paoli Calmettes) andmycophenolate
mofetil (MMF). Tacrolimus (FK 506, at a total dose of 1 mg) was adminis-
tered as a continuous infusion until discharge and was converted to an oral
formulation thereafter. The doses were adjusted to obtain serum levels
between 10 and 20 ng/mL. CsA was dosed at 3 mg/kg as a continuous
infusion until discharge andwas converted to an oral formulation thereafter.
The CsA doses were modiﬁed to obtain serum levels between 100 and
200 ng/mL. MMF was administered at 15 mg/kg per oral 3 times per day
until day þ35 and was then stopped. FK, CsA, and MMF were started on
day þ5. FK and CsA were tapered by day þ180. Granulocyte colonye-
stimulating factor (G-CSF) was started on day þ5 in all patients.
Stem Cell Sources and Donors
Potential family members were typed at the HLA-A, HLA-B, and HLA-
DRB1 loci at an intermediate level of resolution. Selected donors were
typed at the HLA-C locus at an intermediate resolution level. The DRB1 were
typed at a high-resolution level. All donor/recipient pairs exhibited a me-
dian of 4 mismatches (range, 2 to 5) on the unshared haplotype. The donors
underwent BM harvest under general anesthesia, and the target dose was
4108 nuclear cells/kg of recipient weight. Unmanipulated BMwas used for
stem cell support on day 0. In Marseille, the ﬁrst 12 donors underwent BM
harvest, whereas the last cohort of donors (n ¼ 23) were mobilized by the
subcutaneous administration of G-CSF (Neupogen; Filgrastim; Amgen,
Neuilly-sur-Seine, France) for 5 to 6 days at 10 mg/kg/day. The target was a
minimum of 4  106 CD34/kg.
Supportive Care
At both centers, antimicrobial prophylaxis was begun in the hospital
during the conditioning regimen and consisted of acyclovir 500 mg/m2
administered 3 times per day, levoﬂoxacin 500 mg per day, and
sulfamethoxazole þ trimethoprim (160 mg þ 800 mg) administered as 2
tablets per day until day -2 and then resumed after hematological recon-
stitution at a dosage of 1 tablet every other day. The antifungal prophylaxis
programs differed between the 2 centers: in Milan, caspofungin wasadministered (70 mg on the ﬁrst day and then 50 mg per day) until day þ5,
when intravenous itraconazole (200 mg/day) was introduced; in Marseille,
micafungin 50 mg/day was administered. After discharge, the patients
received ﬂuconazole 400 mg/day until day þ75. PCR monitoring of cyto-
megalovirus was performed twice each week from day þ15 until day þ100
and then weekly until day þ180. Treatment with ganciclovir or foscarnet
was started when the number of copies was more than 1000/mL for 2
consecutive weeks. No maintenance treatment was used. In 1 center
(Humanitas Cancer Center), weekly PCR monitoring of Epstein-Barr virus
was started on day þ15, and rituximab (375 mg/m2) was administered if
more than 104 copies/mL were detected.
Engraftment and GVHD Evaluation
Neutrophil engraftment was deﬁned as the ﬁrst of 3 consecutive days
with an ANC of .5  109/L after transplantation. Platelet engraftment was
Table 2
Engraftment Results for all the Patients and for BM- or PBSC-supported
Transplantation
Engraftment Results BM PBSC P Value
ANC >.5  109/L all pts 20 (14-32)
ANC >.5  109/L 21 (14-32) 20 (14-27) .18
PLT >20,000/L all pts 29 (14-52)
PLT >20,000/L 29 (16-46) 27 (14-52) .13
ANC indicates absolute neutrophil count; PLT, platelet count; BM, bone
marrow; PBSC, peripheral blood stem cells; Pts, patients.
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preceding 7 days. Acute GVHDwas graded according to the Keystone criteria
[14], and chronic GVHD was retrospectively graded according to the Na-
tional Institutes of Health criteria [15].HLA Antibody Screening with Microarray Beadebased Assay
IgG anti-HLA reactivity in the sera was tested with a bead-based
screening assay. Brieﬂy, we used the LABScreen Mixed kit (One Lambda
Inc., Canoga Park, CA) which simultaneously detects class I and class II an-
tibodies with microbeads coated with puriﬁed class I and class II HLA an-
tigens. Results above a cut-off value of 3.0 were considered positive. The
Single Antigen kit (One Lambda) was also used to identify HLA speciﬁcities.
The tests were carried out according to the manufacturer instructions and
the analysis was performed with One Lambda software (HLA Fusion Version
3.0). Fluorescence intensity, measured on a Luminex analyzer, indicates the
relative amount of antibody bound to the test sample. All sera with a mean
ﬂuorescence intensity value > 1000 were considered positive.Statistical Analysis
Categorical variables were expressed as proportions and continuous
variables were expressed as the medians with the respective range. Com-
parisons between groups were performed with the chi-squared and Mann-
Whitney tests for categorical and continuous variables, respectively. The
cumulative incidences of aGVHD and cGVHD were estimated considering
disease progression or death as competing events [16]. Nonrelapsemortality
(NRM) was deﬁned as death with no evidence of progression or relapse;
death after disease progression was treated as a competing event in the
NRM calculation. The Kaplan-Meier method was used for the engraftment,
overall survival (OS), and progression-free survival (PFS) analyses [17]. PFS
was deﬁned as the probability of survival without disease recurrence or
progression. All outcomes were calculated from the date of transplantation.
Only patients with successful ANC engraftment were evaluated for aGVHD,
and cGVHD was evaluated only in patients with a minimum follow-up of
100 days. A Cox regression [18] was performed to identify any associations
between GVHD (acute grade II to IV or chronic) and the following variables:
patient age (continuous), donor/patient gender (female/male versus other),
donor/patient cytomegalovirus serology, ABOmatching, donor type (mother
versus other), stem cell source, GVHD prophylaxis (FK versus CsA), and
CD34 þ infusion (continuous). P values .05 were considered signiﬁcant.
SPSS v16.0 and R v2.12.0 software programs were used for the analysis.Figure 1. Cumulative incidence of engraftment by stem cell source. (Left) Shows inc
dicates bone marrow (continuous line); PBSC, peripheral blood stem cells (dashed linRESULTS
The patient characteristics are displayed in Table 1. As
expected, higher numbers of CD34 þ cells were infused in
the PBSC group. Because of the different types of GVHD
prophylaxis used in each center, the patients infused with
BM received either CsA or FK, whereas the patients treated
with PBSCs (originating from Marseille only) received only
CsA. In addition, the PBSC group had a higher hematopoietic
cell transplantation-comorbidity index score.
Engraftment
For the population as a whole, the median time for the
ANC to increase to more than .5  109/L was 20 days
(range,14 to 32), and the median time to an acceptable
transfusion-independent platelet count was 29 days (range,
14 to 52). There were no signiﬁcant differences between the
2 cohorts in terms of the median time to ANC and platelet
reconstitution (Table 2). The cumulative incidences of ANC
and platelet engraftment (Figure 1) were 87% and 95% after
BM and PBSC infusion, respectively (P ¼ .18). The median
time to obtain full donor chimerismwas 60 days (range, 15 to
108), which was similar between the BM and PBSC groups.
GVHD and infectious complications
The incidence of grade II to IV aGVHD was 25% and 33%
after BM and PBSC infusions, respectively (P ¼ .43), and the
incidence of cGVHD was 13% after both BM and PBSC in-
fusions (P ¼ .21) (Figures 2 and 3; Table 3). There were no
signiﬁcant associations between any of the variables and
acute or chronic GVHD (data not shown). The univariate
hazard ratios according to stem cell source (PBSC versus BM)
were 1.61 (95% conﬁdence interval [CI]: .50 to 5.22, P ¼ .43)
and .95 (95% CI: .17 to 5.22, P ¼ .96) for aGVHD grade II to IV
and cGVHD, respectively.
The cumulative incidence of grades III to IV acute GVHD
was 14% in PBSC and 3% in BM group, with a P value of .10.
No major differences between the 2 cohorts were
observed in term of infectious complications (Table 4).
Survival and NRM
Twenty-one patients eventually died: 11 because of pro-
gressive disease and 10 because of transplantation-related
complications. In the latter group, the cause of death was
infection in 7 patients, organ failure in 2 patients, and aGVHD
in 1 patient. After a median follow-up of 18 months (range, 4
to 52 months), the 2-year OS and PFS probability estimates
were 68% and 62%, respectively. The OS and PFS values wereidence of absolute neutrophil count and (Right) shows platelet count. BM in-
e).
Figure 2. Cumulative incidence of acute GVHD (aGVHD) by stem cell source.
BM indicated bone marrow and PBSC, peripheral blood stem cells.
Table 3
Acute and Chronic Graft-versus-Host Disease Incidence and Nonrelapse Rate
Outcome BM PBSC P Value
aGVHD 2-4 all pts 28%
aGVHD 2-4 25% 33% .43
cGVHD all pts 13%
cGVHD 13% 13% .21
NRM all pts 18%
NRM 22% 12% .96
BM indicates bone marrow; PBSC, peripheral blood stem cells; Pts, patients;
aGVDH, acute graft-versus-host disease; cGVHD, chronic graft-versus-host
disease; NRM, nonrelapse mortality.
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(Figures 4 and 5). The relapse incidence was similar between
the 2 cohorts (Figure 6). However, patients in complete
remission had a signiﬁcant lower relapse incidence (14%
versus 33%, P ¼ .04) and superior PFS (68% versus 49%,
P¼ .05) compared with those not in complete remission. The
2-year overall NRM was 18% (BM: 22%; PBSC: 12%; P ¼ .96).Figure 3. Cumulative incidence of chronic GVHD (cGVHD) by stem cell source.
BM indicated bone marrow and PBSC, peripheral blood stem cells.OS and NRM were not statistically different between the 2
cohorts of patients.
DISCUSSION
Haploidentical transplantation with the NMAC regimen,
supported by BM stem cells and postinfusion Cy, has been
reported to be well tolerated, with encouragingly low in-
cidences of GVHD and host versus graft and sustained
engraftment in the majority of patients [11,19].
One of the cornerstones of the Baltimore approachwas the
use of BMasa stemcell source. The reason forusingBMinstead
of PBSCs, evenafterNMAC, is basedonmousemodels, inwhich
different levels of mixed chimerismwere obtained by infusing
a marrow stem cell dose of fewer than 10  106 cells, corre-
sponding to 5  108 mononuclear cells/kg in humans [20].
Furthermore, the lower number and different functional
characteristics of the CD3þ cells contained in BM caused
the use of BM to lower the incidence of acute and chronic
GVHD [21,22]. In human clinical studies involving NMAC or
reduced-intensity conditioning regimens, BM has been
replaced by PBSCs as a stem cell source because of the higher
engraftment rates due to the larger number of CD34þ stem
cells and because of a putatively higher antitumoral effect
linked to a larger number of T cells. However, acute and, in
particular, chronic GVHD occurred more frequently after PBSC
infusions, particularly when NMAC regimens [23] without
in vivo T cell depletionwere used [24,25].
In a prospective phase II study of haploidentical PBSC
infusions using a myeloablative conditioning regimen and
postinfusion Cy, Salomon et al. showed that the cumulative
incidences of grade II to IV aGVHD and cGVHD were 30% and
35% (5% severe), respectively, and that the 1-year NRM was
10%. In that study, 2 peculiar clinical features were observed:
late BK-linked hemorrhagic cystitis (75% of patients) and
cytokine-related fever (90%) after stem cell infusion [12].Table 4






FUO 22% 13% .50
Bacterial sepsis 46% 30% .30
Gram  28% 26%
Gram þ 18% 4%




Not documented 20% 9%
CMV viremia 37% 48% .40
BK-virus HC 11% 0 .10
FUO indicates fever of unknown origin; BM, bone marrow; PBSC, peripheral
blood stem cells; CMV, cytomegalovirus; HC, hemorrhagic cystitis.
Figure 6. Relapse incidence for patients received bone marrow (BM) or pe-
ripheral blood stem cells (PBSC).
Figure 4. Overall survival (OS) for patients received bone marrow (BM) or
peripheral blood stem cells (PBSC).
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outcomes of patients after haploidentical transplantation
using NMAC and postinfusion Cy supported by BM or PBSCs.
The analysis of the ﬁrst clinical endpoint, the incidences of
acute and chronic GVHD, did not reveal any differences
based on the stem cell graft source. We did not observe any
signiﬁcant differences in the rates of acute and chronic
GVHD between the patients receiving PBSCs and those
receiving BM.
The second clinical endpoint analyzed was the engraft-
ment rate. Unpredictably, PBSCs and BM were associated
with similar engraftment rates to achieve both stable ANC
and platelet counts, although the number of CD34-positive
cells was signiﬁcantly higher in the PBSC cohort. This
ﬁnding differed from the usual results of randomized studies
comparing PBSCs with BM after myeloablative conditioning
for HLA-identical transplantation. In a meta-analysis of 9
such studies, the median number of days to safe ANC and
platelet levels was signiﬁcantly shorter in the PBSC group.Figure 5. Progression-free survival (PFS) for patients received bone marrow
(BM) or peripheral blood stem cells (PBSC).Overall, the time to engraftment in our cohort of patients was
longer than that reported by the Baltimore group. In fact, the
latter patients showed a shorter median time to a safe ANC
(15 days versus 20 days in the BM group and 21 days in the
PBSC group), whereas the time to platelet reconstitution was
similar (29 days versus 28 days) between the groups. When
only patients receiving BM were considered, the numbers of
mononuclear cells infused were also similar in the 2 studies.
The most likely reason for this difference is the time until G-
CSF was begun, which was delayed in our patients until
day þ5, as opposed to day þ1 in the Baltimore cohort [26].
Finally, the rates of infectious complications were similar in
the 2 groups. Overall, we conﬁrmed that the risk of oppor-
tunistic infections was not enhanced after haploidentical
transplantation.
This study has several limitations due to its retrospective
nature. The number of patients was quite low in the PBSC
cohort, immunosuppression other than postinfusion Cy was
not homogeneous, and selection bias cannot be excluded.
Overall, this is the ﬁrst study to suggest that, in the setting
of haploidentical transplantation with postinfusion Cy
and NMAC regimens, the use of PBSCs did not appear to be
detrimental to the patients in terms of both GVHD and
engraftment. This ﬁnding could be useful in cases with
difﬁculties accessing an operating room or with a great
disparity in weight between the recipient and donor.
ACKNOWLEDGMENTS
Conﬂict of interest statement: There are no conﬂicts of
interest to report.
Financial disclosure: The authors have nothing to disclose.
REFERENCES
1. Anasetti C, Amos D, Beatty PG, et al. Effect of HLA compatibility on
engraftment of bone marrow transplants in patients with leukemia or
lymphoma. N Engl J Med. 1989;320:197-204.
2. Aversa F, Terenzi A, Tabilio A, et al. Full haplotype-mismatched he-
matopoietic stem-cell transplantation: a phase II study in patients
with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23:
3447-3454.
3. Federmann B, Bornhauser M, Meisner C, et al. Haploidentical allogeneic
hematopoietic cell transplantation in adults using CD3/CD19 depletion
and reduced intensity conditioning: a phase II study. Haematologica.
2012;97:1523-1531.
L. Castagna et al. / Biol Blood Marrow Transplant 20 (2014) 724e729 7294. Ciceri F, Bonini C, Lupo Stanghellini MT, et al. Infusion of suicide-
gene-engineered donor lymphocytes after family haploidentical
haemopoietic stem-cell transplantation for leukaemia (the TK007
trial): a non-randomised phase IeII study. Lancet Oncol. 2009;10:
489-500.
5. Dodero A, Carniti C, Raganato A, et al. Haploidentical stem cell
transplantation after a reduced-intensity conditioning regimen in-
fusions for the treatment of advanced hematologic malignancies:
posttransplantation CD8-depleted donor lymphocyte contribute to
improve T-cell recovery. Blood. 2009;113:4771-4779.
6. Rizzieri DA, Koh LP, Long GD, et al. Partially matched, nonmyeloablative
allogeneic transplantation: clinical outcomes and immune reconstitu-
tion. J Clin Oncol. 2007;25:690-697.
7. Lee K-H, Lee J-H, Lee J-H, et al. Hematopoietic cell transplantation from
an hla-mismatched familial donor is feasible without ex vivo T cell
depletion after reduced-intensity conditioning with busulfan, ﬂudar-
abine, and antithymocyte globulin. Biol Blood Marrow Transplant. 2009;
15:61-72.
8. Huang XJ, Zhu HH, Chang YJ, et al. The superiority of haploidentical
related stem cell transplantation over chemotherapy alone as post-
remission treatment for patients with intermediate- or high-risk acute
myeloid leukemia in ﬁrst complete remission. Blood. 2012;119:
5584-5590.
9. Di Bartolomeo P, Santarone S, De Angelis G, et al. Haploidentical, un-
manipulated, G-CSF-primed bone marrow transplantation for patients
with high-risk hematologic malignancies. Blood. 2013;121:849-857.
10. Santos GW, Owens AH Jr. A comparison of the effects of selected
cytotoxic agents on allogeneic skin graft survival in rats. Bull Johns
Hopkins Hosp. 1965;116:327-340.
11. Luznik L, O’Donnell PV, Symons HJ, et al. HLA-haploidentical bone
marrow transplantation for hematologic malignancies using non-
myeloablative conditioning and high-dose, post-transplantation
cyclophosphamide. Biol Blood Marrow Transplant. 2008;14:641-650.
12. Solomon SR, Sizemore CA, Sanacore M, et al. Haploidentical trans-
plantation using T cell replete peripheral blood stem cells and mye-
loablative conditioning in patients with high-risk hematologic
malignancies who lack conventional donors is well tolerated and
produces excellent relapse-free survival: results of a prospective phase
II trial. Biol Blood Marrow Transplant. 2012;18:1859-1866.
13. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation
(HCT)-speciﬁc comorbidity index: a new tool for risk assessment
before allogeneic HCT. Blood. 2005;106:2912-2919.14. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference
on Acute GVHD Grading. Bone Marrow Transplant. 1995;15:825-828.
15. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health
consensus development project on criteria for clinical trials in chronic
graft-versus-host disease: I. Diagnosis and staging working group
report. Biol Blood Marrow Transplant. 2005;11:945-956.
16. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure
probabilities in the presence of competing risks: new representations
of old estimators. Stat Med. 1999;18:695-706.
17. Kaplan EL, Meier P. Non-parametric estimation from incomplete ob-
servations. J Am Stat Assoc. 1958;53:457-481.
18. Cox D. Regression models and life tables. J R Stat Soc (B). 1972;34:
187-220.
19. Luznik L, Jones RJ, Fuchs EJ. High-dose cyclophosphamide for graft-
versus-host disease prevention. Curr Opin Hematol. 2010;17:493-499.
20. Luznik L, Jalla S, Engstrom LW, et al. Posttransplantation cyclophos-
phamide facilitates engraftment of major histocompatibility com-
plexeidentical allogeneic marrow in mice conditioned with low-dose
total body irradiation. Biol Blood Marrow Transplant. 2002;8:131-138.
21. Ottinger HD, Beelen DW, Scheulen B, et al. Improved immune recon-
stitution after allotransplantation of peripheral blood stem cells
instead of bone marrow. Blood. 1996;88:2775-2779.
22. Korbling M, Anderlini P. Peripheral blood stem cell versus bone
marrow allotransplantation: does the source of hematopoietic stem
cells matter? Blood. 2001;98:2900-2908.
23. Storb R, Gyurkocza B, Storer BE, et al. Graft-versus-host disease and
graft-versus-tumor effects after allogeneic hematopoietic cell trans-
plantation. J Clin Oncol. 2013;31:1530-1538.
24. Peggs KS, Sureda A, Qian W, et al. Reduced-intensity conditioning for
allogeneic haematopoietic stem cell transplantation in relapsed and
refractory Hodgkin lymphoma: impact of alemtuzumab and donor
lymphocyte infusions on long-term outcomes. Br J Haematol. 2007;139:
70-80.
25. Crocchiolo R, Esterni B, Castagna L, et al. Two days of antithymocyte
globulin are associated with a reduced incidence of acute and chronic
graft-versus-host disease in reduced-intensity conditioning trans-
plantation for hematologic diseases. Cancer. 2013;119:986-992.
26. Burroughs LM, O’Donnell PV, Sandmaier BM, et al. Comparison of
outcomes of HLA-matched related, unrelated, or HLA-haploidentical
related hematopoietic cell transplantation following non-
myeloablative conditioning for relapsed or refractory Hodgkin lym-
phoma. Biol Blood Marrow Transplant. 2008;14:1279-1287.
